MX2017016088A - Oligonucleotidos multi-conjugados definidos. - Google Patents
Oligonucleotidos multi-conjugados definidos.Info
- Publication number
- MX2017016088A MX2017016088A MX2017016088A MX2017016088A MX2017016088A MX 2017016088 A MX2017016088 A MX 2017016088A MX 2017016088 A MX2017016088 A MX 2017016088A MX 2017016088 A MX2017016088 A MX 2017016088A MX 2017016088 A MX2017016088 A MX 2017016088A
- Authority
- MX
- Mexico
- Prior art keywords
- defined multi
- conjugate
- conjugate oligonucleotides
- oligonucleotides
- sirna
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Abstract
Se describen oligonucleótidos multi-conjugados definidos pueden tener tamaños y composiciones predeterminados. Por ejemplo, en diversas modalidades, los oligonucleótidos multi-conjugados definidos pueden tener propiedades adecuadas, por ejemplo en forma de siARN multi-conjugado definido (es decir, que incluye dos, tres o más siARN) que tiene administración intracelular potenciada y/o efectos de silenciamiento multigénico. En diversas modalidades, los oligonucleótidos multi-conjugados definidos pueden sintetizarse a través de nuevos intermedios sintéticos y métodos. Los oligonucleótidos multi-conjugados definidos pueden usarse, por ejemplo, para reducir la expresión génica, investigación biológica, tratar o prevenir afecciones médicas, o para producir fenotipos nuevos o alterados en células u organismos.
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562175718P | 2015-06-15 | 2015-06-15 | |
US201562175709P | 2015-06-15 | 2015-06-15 | |
US201562175714P | 2015-06-15 | 2015-06-15 | |
US201562203243P | 2015-08-10 | 2015-08-10 | |
US201562216317P | 2015-09-09 | 2015-09-09 | |
US201562216318P | 2015-09-09 | 2015-09-09 | |
US201562216314P | 2015-09-09 | 2015-09-09 | |
PCT/US2016/037685 WO2016205410A2 (en) | 2015-06-15 | 2016-06-15 | Defined multi-conjugate oligonucleotides |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017016088A true MX2017016088A (es) | 2018-04-11 |
Family
ID=57546088
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017016088A MX2017016088A (es) | 2015-06-15 | 2016-06-15 | Oligonucleotidos multi-conjugados definidos. |
Country Status (11)
Country | Link |
---|---|
US (2) | US11352629B2 (es) |
EP (1) | EP3307889A4 (es) |
JP (1) | JP7033452B2 (es) |
KR (1) | KR20180039621A (es) |
CN (1) | CN108026527B (es) |
AU (2) | AU2016280709B2 (es) |
CA (1) | CA2988603A1 (es) |
HK (1) | HK1252970A1 (es) |
IL (1) | IL256169A (es) |
MX (1) | MX2017016088A (es) |
WO (1) | WO2016205410A2 (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101141544B1 (ko) | 2009-03-13 | 2012-05-03 | 한국과학기술원 | 에스아이알엔에이 다중 접합체 및 이의 제조방법 |
KR20180039621A (ko) | 2015-06-15 | 2018-04-18 | 엠펙 엘에이, 엘엘씨 | 정의된 다중 접합체 올리고뉴클레오티드 |
US10478503B2 (en) | 2016-01-31 | 2019-11-19 | University Of Massachusetts | Branched oligonucleotides |
WO2018013640A1 (en) | 2016-07-15 | 2018-01-18 | University Of Massachusetts | Process of delivering small rnas to sperm |
WO2018031933A2 (en) | 2016-08-12 | 2018-02-15 | University Of Massachusetts | Conjugated oligonucleotides |
EP3576752A4 (en) | 2017-02-06 | 2020-12-16 | Mpeg La, LLC | MULTIMERIC OLIGONUCLEOTIDES WITH REDUCED RENAL CLEARANCE |
AU2018330495A1 (en) | 2017-09-08 | 2020-03-26 | Mina Therapeutics Limited | Stabilized hnf4a sarna compositions and methods of use |
US20210052706A1 (en) * | 2018-01-10 | 2021-02-25 | Translate Bio Ma, Inc. | Compositions and methods for facilitating delivery of synthetic nucleic acids to cells |
CN111886231B (zh) | 2018-04-05 | 2023-08-01 | 株式会社Lg化学 | 基于咔唑的化合物和包含其的有机发光器件 |
KR20210093227A (ko) | 2018-08-10 | 2021-07-27 | 유니버시티 오브 매사추세츠 | Snp를 표적화하는 변형된 올리고뉴클레오티드 |
EP3856200A4 (en) * | 2018-09-28 | 2022-07-20 | Sirnaomics, Inc. | MULTI-TARGETING MULTI-OLIGONUCLEOTIDE NUCLEIC ACID CONSTRUCTS THAT MODULATE GENE EXPRESSION THROUGH COMPLEMENTARY INTERACTIONS WITH TARGETS |
CA3132505A1 (en) * | 2019-03-04 | 2020-09-10 | Mpeg La, L.L.C. | Multimeric oligonucleotides with enhanced bioactivity |
EP3952919A2 (en) * | 2019-04-11 | 2022-02-16 | Northeastern University | Oligonucleotide-polymer miktoarm conjugates and methods of use |
CA3144467A1 (en) * | 2019-07-30 | 2021-02-04 | Jonathan Miles Brown | Subcutaneous delivery of multimeric oligonucleotides with enhanced bioactivity |
CN111041025B (zh) | 2019-12-17 | 2021-06-18 | 深圳市瑞吉生物科技有限公司 | 基于结合N-乙酰半乳糖胺多肽的mRNA靶向分子及其制备方法 |
CN112111524B (zh) * | 2020-01-10 | 2024-02-27 | 深圳瑞吉生物科技有限公司 | mRNA-GalNAc靶向分子的制备方法及其体内递送系统和应用 |
MX2022013475A (es) * | 2020-04-30 | 2022-11-30 | Mpeg La L L C | Oligonucleotidos multimericos con cadenas divididas. |
KR20230012527A (ko) * | 2020-05-19 | 2023-01-26 | 엠펙 엘에이, 엘.엘.씨. | 직교 연결된 다량체성 올리고뉴클레오타이드 |
CN111744019B (zh) | 2020-07-01 | 2023-08-04 | 深圳瑞吉生物科技有限公司 | 基于甘露糖的mRNA靶向递送系统及其应用 |
EP4359539A1 (en) | 2021-06-23 | 2024-05-01 | University Of Massachusetts | Optimized anti-flt1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders |
CN115010794A (zh) * | 2022-06-30 | 2022-09-06 | 武汉瑞佶生物科技有限公司 | 蛋白质介导的mRNA靶向分子及其制备方法和应用 |
WO2024061157A1 (en) * | 2022-09-19 | 2024-03-28 | Kylonova (Xiamen) Biopharma Co., Ltd. | Carbohydrate-oligonucleotide conjugates, pharmaceutical compositions, and therapeutic applications |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9207381D0 (en) | 1992-04-03 | 1992-05-13 | Ici Plc | Synthesis of oligonucleotides |
WO2004030634A2 (en) | 2002-10-02 | 2004-04-15 | Alnylam Pharmaceuticals Inc. | Therapeutic compositions |
EP1605978B1 (en) | 2003-03-07 | 2010-09-01 | Alnylam Pharmaceuticals Inc. | Therapeutic compositions |
JP2006522158A (ja) | 2003-04-03 | 2006-09-28 | アルナイラム ファーマシューティカルズ インコーポレイテッド | iRNA複合体 |
US8969543B2 (en) | 2003-04-03 | 2015-03-03 | Bioneer Corporation | SiRNA-hydrophilic polymer conjugates for intracellular delivery of siRNA and method thereof |
CA2521464C (en) | 2003-04-09 | 2013-02-05 | Alnylam Pharmaceuticals, Inc. | Irna conjugates |
AU2004230927B9 (en) | 2003-04-13 | 2011-12-01 | Enzon Pharmaceuticals, Inc. | Polymeric oligonucleotide prodrugs |
EP2664672A1 (en) | 2003-04-17 | 2013-11-20 | Alnylam Pharmaceuticals Inc. | Modified iRNA agents |
AU2004232964B2 (en) | 2003-04-17 | 2011-09-22 | Alnylam Pharmaceuticals, Inc. | Protected monomers |
US7851615B2 (en) | 2003-04-17 | 2010-12-14 | Alnylam Pharmaceuticals, Inc. | Lipophilic conjugated iRNA agents |
PL1807520T3 (pl) | 2004-10-25 | 2013-01-31 | Devgen Nv | Konstrukty do RNA |
ES2564303T3 (es) | 2006-04-07 | 2016-03-21 | Idera Pharmaceuticals, Inc. | Compuestos de ARN inmunomodulador estabilizado (SIMRA) para TLR7 y TLR8 |
WO2008094254A2 (en) | 2007-01-26 | 2008-08-07 | City Of Hope | Methods and compositions for the treatment of cancer or other diseases |
US20080287383A1 (en) | 2007-03-02 | 2008-11-20 | Nastech Pharmaceutical Company Inc. | Nucleic acid compounds for inhibiting erbb gene expression and uses thereof |
US20080311040A1 (en) | 2007-03-06 | 2008-12-18 | Flagship Ventures | METHODS AND COMPOSITIONS FOR IMPROVED THERAPEUTIC EFFECTS WITH siRNA |
CN102921003B (zh) | 2007-07-09 | 2014-11-26 | 艾德拉药物股份有限公司 | 稳定化免疫调控性rna(simra)化合物 |
EP3604533A1 (en) | 2008-04-11 | 2020-02-05 | Arbutus Biopharma Corporation | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
EP2323695B1 (en) | 2008-08-19 | 2018-12-05 | Nektar Therapeutics | Complexes of small-interfering nucleic acids |
US8637194B2 (en) * | 2008-09-02 | 2014-01-28 | Bio-Nano Power, Llc | Bio-nano power cells and their uses |
JP5645840B2 (ja) * | 2008-12-02 | 2014-12-24 | 株式会社Wave Life Sciences Japan | リン原子修飾核酸の合成方法 |
WO2010090762A1 (en) * | 2009-02-04 | 2010-08-12 | Rxi Pharmaceuticals Corporation | Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
KR101141544B1 (ko) | 2009-03-13 | 2012-05-03 | 한국과학기술원 | 에스아이알엔에이 다중 접합체 및 이의 제조방법 |
WO2011031520A1 (en) | 2009-08-27 | 2011-03-17 | Idera Pharmaceuticals, Inc. | Composition for inhibiting gene expression and uses thereof |
KR101678876B1 (ko) | 2010-01-15 | 2016-11-23 | 한국과학기술원 | 복합 유전자를 표적하는 siRNA 다중 접합체 및 이의 제조방법 |
SI2539451T1 (sl) | 2010-02-24 | 2016-04-29 | Arrowhead Research Corporation | Sestavki za ciljano dostavo sirna |
EP2542247A4 (en) | 2010-03-01 | 2014-05-07 | Philadelphia Children Hospital | NUCLEIC ACID FOR ADDRESSING MULTIPLE REGIONS OF THE HCV GENOM |
JP6128529B2 (ja) * | 2011-07-19 | 2017-05-17 | ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. | 官能化核酸の合成のための方法 |
KR101340290B1 (ko) * | 2011-09-14 | 2013-12-11 | 한국과학기술원 | 유전자 표적용 siRNA 하이드로젤 및 그 제조방법 |
US9580708B2 (en) | 2011-09-14 | 2017-02-28 | Rana Therapeutics, Inc. | Multimeric oligonucleotides compounds |
WO2014043544A1 (en) | 2012-09-14 | 2014-03-20 | Rana Therapeutics, Inc. | Multimeric oligonucleotide compounds |
KR101629681B1 (ko) * | 2013-06-24 | 2016-06-14 | 건국대학교 산학협력단 | 다중 리간드가 도입된 에스아이알엔에이 접합체 |
EP2845607A1 (en) | 2013-09-09 | 2015-03-11 | University of Vienna | Antisense oligonucleotides with improved pharmacokinetic properties |
AU2014362262B2 (en) | 2013-12-12 | 2021-05-13 | Alnylam Pharmaceuticals, Inc. | Complement component iRNA compositions and methods of use thereof |
JP2017505623A (ja) | 2014-01-30 | 2017-02-23 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 生物切断性コンジュゲートを有するポリオリゴマー化合物 |
KR20180039621A (ko) | 2015-06-15 | 2018-04-18 | 엠펙 엘에이, 엘엘씨 | 정의된 다중 접합체 올리고뉴클레오티드 |
WO2017075030A1 (en) | 2015-10-26 | 2017-05-04 | Rana Therapeutics, Inc. | Methods and compositions for increasing smn expression |
IL294411A (en) | 2016-01-05 | 2022-08-01 | Omeros Corp | masp-2 suppressors for use in suppressing fibrosis |
EP3576752A4 (en) | 2017-02-06 | 2020-12-16 | Mpeg La, LLC | MULTIMERIC OLIGONUCLEOTIDES WITH REDUCED RENAL CLEARANCE |
CN111741967A (zh) | 2017-11-30 | 2020-10-02 | 深圳市真迈生物科技有限公司 | 核苷类似物、制备方法及应用 |
CA3144467A1 (en) | 2019-07-30 | 2021-02-04 | Jonathan Miles Brown | Subcutaneous delivery of multimeric oligonucleotides with enhanced bioactivity |
-
2016
- 2016-06-15 KR KR1020187001337A patent/KR20180039621A/ko not_active Application Discontinuation
- 2016-06-15 AU AU2016280709A patent/AU2016280709B2/en active Active
- 2016-06-15 EP EP16812366.9A patent/EP3307889A4/en active Pending
- 2016-06-15 JP JP2017565893A patent/JP7033452B2/ja active Active
- 2016-06-15 MX MX2017016088A patent/MX2017016088A/es unknown
- 2016-06-15 US US15/735,707 patent/US11352629B2/en active Active
- 2016-06-15 CN CN201680048179.5A patent/CN108026527B/zh active Active
- 2016-06-15 CA CA2988603A patent/CA2988603A1/en active Pending
- 2016-06-15 WO PCT/US2016/037685 patent/WO2016205410A2/en active Application Filing
-
2017
- 2017-12-07 IL IL256169A patent/IL256169A/en unknown
-
2018
- 2018-09-26 HK HK18112329.7A patent/HK1252970A1/zh unknown
-
2022
- 2022-05-18 US US17/747,924 patent/US11767531B2/en active Active
- 2022-12-08 AU AU2022283737A patent/AU2022283737A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
IL256169A (en) | 2018-03-29 |
CA2988603A1 (en) | 2016-12-22 |
KR20180039621A (ko) | 2018-04-18 |
AU2016280709B2 (en) | 2022-09-15 |
CN108026527A (zh) | 2018-05-11 |
WO2016205410A3 (en) | 2017-02-09 |
US11352629B2 (en) | 2022-06-07 |
US11767531B2 (en) | 2023-09-26 |
CN108026527B (zh) | 2022-05-10 |
HK1252970A1 (zh) | 2019-06-06 |
US20220290148A1 (en) | 2022-09-15 |
AU2016280709A1 (en) | 2018-01-04 |
WO2016205410A2 (en) | 2016-12-22 |
US20190085331A1 (en) | 2019-03-21 |
AU2022283737A1 (en) | 2023-02-02 |
EP3307889A2 (en) | 2018-04-18 |
JP2018518186A (ja) | 2018-07-12 |
EP3307889A4 (en) | 2019-06-26 |
JP7033452B2 (ja) | 2022-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017016088A (es) | Oligonucleotidos multi-conjugados definidos. | |
MX2015008697A (es) | Tratamiento contra la degeneración macular relacionada con la edad. | |
PH12017500424A1 (en) | Mir-29 mimics and uses thereof | |
BR112017013597A2 (pt) | molécula de ácido nucleico, composição farmacêutica, vetor ou célula, e, método para tratamento de uma doença. | |
MX2018006116A (es) | Materiales y metodos para el tratamiento de miopatias basadas en titina y otras titinopatias. | |
MX2017004890A (es) | Metodos y composiciones para la generación o el mantenimiento de células pluripotentes. | |
PH12019500626A1 (en) | Aav treatment of huntington's disease | |
TR201901939T4 (tr) | Antisens nükleik asit. | |
SG10201809290SA (en) | Compositions and Methods to Treating Hemoglobinopathies | |
SG195194A1 (en) | Nanogels | |
EA201490563A1 (ru) | Антисмысловые олигонуклеотиды для лечения врожденного амавроза лебера | |
EP3620178A3 (en) | Antisense antibacterial compounds and methods | |
MX2021006745A (es) | Constructos de iarn modificados quimicamente y usos de estos. | |
MX2017014641A (es) | Composiciones y metodos para inhibir la expresion del gen de factor inducible por hipoxia alfa (hif2alfa). | |
MX2019005101A (es) | Microarns modificados con 5-halouracilo y su uso en el tratamiento del cancer. | |
NZ737542A (en) | Mir-155 inhibitors for treating cutaneous t cell lymphoma (ctcl) | |
MX2022001017A (es) | Composiciones y metodos para inhibir la expresion del gen de sintasa de acido 5'-aminolevulinico 1 (alas1). | |
SG10201811574YA (en) | Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers | |
MX2015012063A (es) | Oligonucleotidos antisentido para el tratamiento de celulas madre del cancer. | |
MX2022005790A (es) | Elementos reguladores de planta y metodos para usarlos. | |
MX2016004212A (es) | Inhibidor de tor cinasa en la prevencion o tratamiento de cancer caracterizado por mutaciones genicas. | |
WO2011103028A3 (en) | Compositions and methods for inhibiting mmset | |
WO2015020993A3 (en) | RNAi COMPOSITIONS AND METHODS FOR TREATMENT OF FRIEDREICH'S ATAXIA | |
WO2020104649A3 (en) | Novel rna compositions and methods for inhibiting angptl8 | |
MX368084B (es) | siRNA Y SU USO EN LA PREPARACIÓN DE UN MEDICAMENTO PARA USARSE EN UN MÉTODO PARA EL TRATAMIENTO DE UN TRANSTORNO OCULAR. |